Evolving Paradigms, CAR T, and Treatment Selection in Early-Stage R/R MM
The panelist discusses how the treatment landscape for early-stage relapsed/refractory multiple myeloma (R/R MM) has evolved significantly with CAR T-cell therapies (idecabtagene vicleucel, ciltacabtagene autoleucel [ide-cel, cilta-cel]) and novel drug combinations. Treatment selection now considers prior therapies, patient characteristics, and response duration. For third-line chimeric antigen receptor (CAR) T after no prior CAR T use, cilta-cel shows favorable efficacy data with deeper, more durable responses than ide-cel, though both are viable options.
Video content above is prompted by the following:
- How has the treatment landscape evolved for patients with early-stage R/R MM?
- How has the evolving paradigm affected your approach to treatment selection and sequencing in early-stage R/R MM?
- For patients not previously treated with CAR T in the second line (2L), what choice of CAR T therapy would you consider in the 3L setting?
- What factors inform your selection of CAR T beyond the 2L setting in MM?
- What lessons have you learned from bridging therapy, and how would you advise on optimal strategies?
Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma
February 22nd 2025In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.
Read More
Key Trials From ASH 2024 Impact Treatment for Plasma Cell Disorders Going Forward
February 20th 2025Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 ASH Annual Meeting and Exposition.
Read More
